Zenas Biopharma Inc (ZBIO) — Who's Buying and Selling (13F, Q2 2026)

ZBIO ranks #3699 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ZBIO is a top-conviction position for Enavate Sciences GP, LLC — at 28.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ZBIO belongs to FMR LLC, but the position matters far more to Enavate Sciences GP, LLC, who has 28.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

State Street has added to its ZBIO position for two straight quarters, increasing it by $36.2M to reach $52.2M today.

Invesco Ltd. has trimmed its ZBIO position for two straight quarters, cutting it by $6.3M while still holding $481.1K.

ZBIO is up 3.6% today, and institutions have been net buyers of $151.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ZBIO reported a net loss of $484.4M over the trailing twelve months.

• Not yet profitable — net loss of $484.4M over the trailing twelve months
• Revenue declined 98.3% year over year
• Net income declined year over year, from -$177.0M to -$484.4M
• Operating cash flow was negative, using $172.3M in cash
• Current ratio of 5.61x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.58x equity — within a conventional range